文献速递炎症性肠病

溃疡性结肠炎患者托法替布治疗中STAT3磷酸化与组织学结局的纵向监测

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-04-28

该研究前瞻性监测59例高度难治性溃疡性结肠炎患者启动托法替布治疗,在诱导结束时和48周评估结局。第8周和第48周分别有24.4%和30.5%的患者达到内镜改善,内镜缓解和组织学缓解率分别为11.1%、23.7%和16.7%、21.4%。第8周内镜改善与长期继续治疗显著相关(72.7% vs 20.6%,p=0.003)。

要点

  • 托法替布可使高达四分之一的难治性溃疡性结肠炎患者获得内镜和组织学缓解。
  • 第8周内镜改善与长期继续治疗相关(72.7% vs 20.6%,p=0.003)。
  • 黏膜pSTAT3水平在缓解者和未缓解者中均逐渐下降(p<0.05),但与治疗结局无关联。

核心结论

  • 托法替布可诱导和维持高度难治性溃疡性结肠炎患者的内镜和组织学缓解,比例高达四分之一。
  • 黏膜组织隔室中核pSTAT3的纵向监测反映了独特的目标效应,与长期治疗结局无关。

研究设计与样本

  • 前瞻性监测在两家炎症性肠病转诊中心启动托法替布治疗的59例高度难治性患者(96.7%有抗TNF暴露史,91.7%有维得利珠单抗暴露史)。
  • 在诱导结束时和48周治疗结束时评估结局,使用多重免疫组化与多光谱成像评估pSTAT3。

主要发现

  • 第8周和第48周分别有24.4%和30.5%的患者达到内镜改善(Mayo内镜亚评分≤1)。
  • 内镜缓解率和组织学缓解率分别在第8周为11.1%和16.7%,在第48周为23.7%和21.4%。
  • 第8周内镜改善与长期继续治疗显著相关(72.7% vs 20.6%,p=0.003)。
  • 黏膜pSTAT3水平在缓解者和未缓解者中均逐渐下降(p<0.05),但与治疗结局无关联。
  • 固有层pSTAT3与Nancy组织学指数显著相关(p=0.004)。

关键数值与推荐

  • 内镜改善定义为Mayo内镜亚评分≤1,内镜和组织学缓解定义为Mayo内镜亚评分0和Nancy组织学评分0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is the first in class, pan-JAK inhibitor approved for ulcerative colitis (UC). Clinical efficacy has been shown, but long-term real-life endoscopic and histologic data are lacking. AIM: To investigate the effects of tofacitinib in patients with refractory UC focussing on endoscopic, histologic and molecular outcomes, including STAT3 phosphorylation (pSTAT3) detection in the spatial context of mucosal inflammation METHODS: We prospectively monitored 59 highly refractory patients (96.7% anti-TNF exposure, 91.7% vedolizumab exposure) initiating tofacitinib at two IBD referral centres and assessed outcome at the end of induction and after 48 weeks of therapy. Endoscopic improvement was defined as a Mayo endoscopic subscore ≤1, endoscopic and histologic remission as Mayo endoscopic subscore 0 and Nancy histologic score 0. Multiplex immunohistochemistry with multispectral imaging was used to assess pSTAT3. RESULTS: Endoscopic improvement was achieved by 24.4% and 30.5% of patients at weeks 8 and 48, respectively. Endoscopic and histologic remission rates were 11.1%, 23.7 and 16.7%, 21.4%, respectively. Endoscopic improvement at week 8 was significantly associated with treatment continuation in the long-term (72.7% vs 20.6%, p = 0.003). Although we observed a gradual decrease of mucosal pSTAT3 levels in both remitters and non-remitters (p < 0.05), no association with treatment outcome could be demonstrated. However, lamina propria pSTAT3 was significantly associated with the Nancy Histologic index (p = 0.004). CONCLUSION: Tofacitinib can induce and maintain endoscopic and histologic remission in up to one-quarter of highly refractory UC patients. Longitudinal monitoring of nuclear pSTAT3 in mucosal tissue compartments reflects distinctive on-target effects, independently of long-term treatment outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Verstockt B, Volk V, Jaeckel C, et al. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022. PMID: 35484689. doi:10.1111/apt.16955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。